Gartner® Predicts 70% of Payers Will Address Workflow, Data and Service Automation using No-Code AI Agent Builders (NCABs) by 2028; Ushur Named a Representative Provider

Ushur was named a “Representative Provider” in Gartner’s March 17, 2026 report on no-code AI agent builders for U.S. healthcare payers, highlighting that by 2028, 70% of payers will use NCABs to automate workflows and cut manual workload by 50%. The announcement positions Ushur’s auditable, regulated AI agent platform as infrastructure for reducing administrative costs while supporting compliance-heavy use cases like prior authorizations and eligibility verification.

Analysis

This is more of a category-validation signal than a company-specific revenue driver. For IT, the only direct read-through is reputational: Gartner’s continued framing of AI workflow tooling as an enterprise buying standard reinforces the long-run utility of its research franchise, but it does not materially move near-term bookings or renewal rates on its own. The bigger market implication is that payer buyers will likely use analyst coverage to justify budget shifts from human labor and legacy BPM toward governed automation, which is supportive for platform vendors with compliance controls and repeatable deployment paths.

The second-order winner set is broader than the named vendor. If the workflow use case gets real budget, the most leverage sits with horizontal platforms that can own orchestration and audit trails, not pure chatbot vendors: NOW and PEGA are better positioned than point solutions because they can attach to existing enterprise workflows. On the payer side, the eventual margin benefit accrues to insurers with the best execution on automation, but that is a 6-18 month story and likely shows up first in SG&A ratio improvement rather than top-line acceleration.

The contrarian view is that this could be overread as adoption when it is still mostly procurement theater. Gartner inclusion is not proof of scale, and healthcare payer AI rollouts often stall at security review, PHI governance, and change management. The key falsifier is not another press release; it is whether a named payer customer references measurable handle-time reduction, claims/admin cost improvement, or visible SG&A leverage in upcoming earnings cycles. If that doesn’t happen over the next 1-2 quarters, the move in AI workflow beneficiaries is likely to fade.

Key Decisions for Investors

• No immediate trade in IT on this headline alone; keep it as a sentiment tailwind, not a catalyst, unless Gartner commentary begins to show measurable contribution to subscription growth in the next 1-2 quarters.
• Watch/accumulate NOW and PEGA on any pullback over the next 1-3 months if payer automation budgets are confirmed in channel checks; these names have better operating leverage to governed workflow adoption than point AI vendors.
• Pair trade idea: long NOW / short a basket of less-governed conversational AI vendors or generalist AI names with weaker compliance moats; thesis only works if healthcare buyers prioritize auditability over novelty.
• For payer operators (UNH, CVS, ELV), treat this as a 6-18 month margin story rather than an immediate revenue catalyst; buy only if subsequent earnings show SG&A or admin ratio inflection, otherwise fade the enthusiasm.
• Falsifier alert: if the next 1-2 major payer earnings calls do not mention real workflow automation savings or if implementation timelines slip beyond 2H26, reduce exposure to the automation theme.